Tags : R-Pharm

Oncology Venture Signs an Exclusive Option Agreement to In-License Commercialization

Shots: Oncology to evaluate Ixempra (ixabepilone) in combination with DRP CDx for metastatic breast cancer in EU. Post the results of trial, Oncology has an exclusive option to in-license commercialization rights for Ixempra in EU The focus of the in-licensing agreement is to utilize Oncology Ventures’ Drug Response Prediction (DRP) biomarker platform for the enhancement […]Read More